Free tool
FAERS Monitor: Dymista
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202236 or its brand name (Dymista, Azelastine Hydrochloride, Fluticasone Propionate). Reports on generic versions are filed under their own applications.
Reports
4,131
Serious
2,443
59% of reports
Hospitalization
913
Death reported
65
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea328
- drug ineffective311
- fatigue287
- headache278
- asthma267
- cough256
- nausea241
- sinusitis204
- pneumonia202
- dizziness180
- off label use176
- diarrhoea158
- malaise148
- condition aggravated139
- pain138
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 5 |
| 2013 | 19 |
| 2014 | 72 |
| 2015 | 556 |
| 2016 | 444 |
| 2017 | 334 |
| 2018 | 366 |
| 2019 | 395 |
| 2020 | 390 |
| 2021 | 272 |
| 2022 | 257 |
| 2023 | 254 |
| 2024 | 321 |
| 2025 | 266 |
| 2026 | 179 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,028 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 267 | 12.1 | 10.7 | 2,704 |
| sinusitisSignal | 204 | 10.2 | 8.9 | 1,679 |
| coughSignal | 256 | 4.7 | 4.1 | 739 |
| pneumoniaSignal | 202 | 3.2 | 2.8 | 304 |
| dyspnoeaSignal | 328 | 3.0 | 2.7 | 433 |
| condition aggravatedSignal | 139 | 2.3 | 2.0 | 105 |
| headacheSignal | 278 | 2.3 | 2.0 | 199 |
| fatigue | 287 | 1.9 | 1.7 | 121 |
| dizziness | 180 | 1.8 | 1.6 | 70 |
| malaise | 148 | 1.7 | 1.5 | 45 |
| nausea | 241 | 1.6 | 1.4 | 48 |
| diarrhoea | 158 | 1.2 | 1.1 | 8 |
| drug ineffective | 311 | 1.2 | 1.1 | 11 |
| pain | 138 | 1.1 | 1.0 | 2 |
| off label use | 176 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.